Literature DB >> 18450872

Early diagnosis of fibrodysplasia ossificans progressiva.

Frederick S Kaplan1, Meiqi Xu, David L Glaser, Felicity Collins, Michael Connor, Joseph Kitterman, David Sillence, Elaine Zackai, Vardit Ravitsky, Michael Zasloff, Arupa Ganguly, Eileen M Shore.   

Abstract

BACKGROUND: Fibrodysplasia ossificans progressiva is a rare and disabling genetic condition characterized by congenital malformation of the great toes and by progressive heterotopic ossification in specific anatomic patterns. Most patients with fibrodysplasia ossificans progressiva are misdiagnosed early in life before the appearance of heterotopic ossification and undergo diagnostic procedures that can cause lifelong disability. Recently, the genetic cause of fibrodysplasia ossificans progressiva was identified, and definitive genetic testing for fibrodysplasia ossificans progressiva is now available before the appearance of heterotopic ossification.
METHODS: We recently evaluated 7 children for diagnosis of fibrodysplasia ossificans progressiva before the onset of heterotopic ossification. A medical history, physical examination, and skeletal survey were obtained on all of the patients, as well as clinical genetic testing for the canonical fibrodysplasia ossificans progressiva mutation.
RESULTS: All 7 of the children (4 girls and 3 boys; ages 3 months to 6 years) had congenital malformations of the great toes, but none had radiographic evidence of heterotopic ossification at the time of evaluation. Five of the 7 children had soft tissue lesions of the neck and back, suggestive of early fibrodysplasia ossificans progressiva flare-ups, 3 of whom had undergone invasive diagnostic procedures that exacerbated their condition. Two children had no history or signs of soft tissue swelling or flare-ups. DNA sequence analysis found that all 7 of the children had the recurrent fibrodysplasia ossificans progressiva missense mutation, a single nucleotide substitution (c.617G>A) at codon 206 in the glycine-serine activation domain of activin receptor IA, a bone morphogenetic protein type 1 receptor.
CONCLUSION: Clinical suspicion of fibrodysplasia ossificans progressiva early in life on the basis of malformed great toes can lead to early clinical diagnosis, confirmatory diagnostic genetic testing, and the avoidance of additional harmful diagnostic and treatment procedures. This is the first report of genetic confirmation of fibrodysplasia ossificans progressiva before the appearance of heterotopic ossification. Pediatricians should be aware of the early diagnostic features of fibrodysplasia ossificans progressiva, even before the appearance of heterotopic ossification. This awareness should prompt early genetic consultation and testing and the institution of assiduous precautions to prevent iatrogenic harm.

Entities:  

Mesh:

Year:  2008        PMID: 18450872      PMCID: PMC3502043          DOI: 10.1542/peds.2007-1980

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  16 in total

1.  Fibrodysplasia ossificans progressiva in two half-sisters: evidence for maternal mosaicism.

Authors:  H B Janoff; M Muenke; L O Johnson; A Rosenberg; E M Shore; E Okereke; M Zasloff; F S Kaplan
Journal:  Am J Med Genet       Date:  1996-02-02

2.  Catastrophic falls in patients who have fibrodysplasia ossificans progressiva.

Authors:  D L Glaser; D M Rocke; F S Kaplan
Journal:  Clin Orthop Relat Res       Date:  1998-01       Impact factor: 4.176

3.  The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients.

Authors:  R B Cohen; G V Hahn; J A Tabas; J Peeper; C L Levitz; A Sando; N Sando; M Zasloff; F S Kaplan
Journal:  J Bone Joint Surg Am       Date:  1993-02       Impact factor: 5.284

4.  Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva.

Authors:  F S Kaplan; C M Strear; M A Zasloff
Journal:  Clin Orthop Relat Res       Date:  1994-07       Impact factor: 4.176

5.  Fibrodysplasia ossificans progressiva.

Authors:  S Mahboubi; D L Glaser; E M Shore; F S Kaplan
Journal:  Pediatr Radiol       Date:  2001-05

6.  Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva.

Authors:  T F Lanchoney; R B Cohen; D M Rocke; M A Zasloff; F S Kaplan
Journal:  J Pediatr       Date:  1995-05       Impact factor: 4.406

7.  Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva.

Authors:  W Luchetti; R B Cohen; G V Hahn; D M Rocke; M Helpin; M Zasloff; F S Kaplan
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1996-01

8.  Genetic transmission of fibrodysplasia ossificans progressiva. Report of a family.

Authors:  F S Kaplan; W McCluskey; G Hahn; J A Tabas; M Muenke; M A Zasloff
Journal:  J Bone Joint Surg Am       Date:  1993-08       Impact factor: 5.284

9.  Age- and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva.

Authors:  D M Rocke; M Zasloff; J Peeper; R B Cohen; F S Kaplan
Journal:  Clin Orthop Relat Res       Date:  1994-04       Impact factor: 4.176

10.  The histopathology of fibrodysplasia ossificans progressiva. An endochondral process.

Authors:  F S Kaplan; J A Tabas; F H Gannon; G Finkel; G V Hahn; M A Zasloff
Journal:  J Bone Joint Surg Am       Date:  1993-02       Impact factor: 5.284

View more
  52 in total

1.  An unusual complication of an infiltrated intravenous catheter: heterotopic ossification in a newborn.

Authors:  Lavi Nissim; Dorothy Gilbertson-Dahdal
Journal:  J Radiol Case Rep       Date:  2008-08-01

2.  Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Petra Seemann; Julia Haupt; Meiqi Xu; Vitali Y Lounev; Mary Mullins; Eileen M Shore
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

3.  Osteochondromas in fibrodysplasia ossificans progressiva: a widespread trait with a streaking but overlooked appearance when arising at femoral bone end.

Authors:  A Morales-Piga; J Bachiller-Corral; P González-Herranz; M Medrano-SanIldelfonso; J Olmedo-Garzón; G Sánchez-Duffhues
Journal:  Rheumatol Int       Date:  2015-06-07       Impact factor: 2.631

4.  Is fibrodysplasia ossificans progressiva ever seen without skeletal abnormalities?

Authors:  Sumeet Gulshan Dua; Nilendu C Purandare
Journal:  Rheumatol Int       Date:  2011-03-25       Impact factor: 2.631

5.  Fibrodysplasia ossificans progressiva without characteristic skeletal anomalies.

Authors:  Hasan Ulusoy
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

6.  Clinical Utility Gene Card for: Fibrodysplasia ossificans progressiva.

Authors:  Nathalie Bravenboer; Dimitra Micha; James T Triffit; Alex N Bullock; Roberto Ravazollo; Renata Bocciardi; Maja di Rocco; J Coen Netelenbos; Peter Ten Dijke; Gonzalo Sánchez-Duffhues; Fred S Kaplan; Eileen M Shore; Robert J Pignolo; Petra Seemann; Francesc Ventura; Genevieve Beaujat; Elizabeth M W Eekhoff; Gerard Pals
Journal:  Eur J Hum Genet       Date:  2015-01-21       Impact factor: 4.246

Review 7.  Cellular and morphological aspects of fibrodysplasia ossificans progressiva. Lessons of formation, repair, and bone bioengineering.

Authors:  Anderson Martelli; Arnaldo Rodrigues Santos
Journal:  Organogenesis       Date:  2014-10-31       Impact factor: 2.500

8.  Pregnancy in fibrodysplasia ossificans progressiva.

Authors:  Javaid A Muglu; Aditya Garg; T Pandiarajan; Eileen M Shore; Frederick S Kaplan; Dhiraj Uchil; Malcolm J Dickson
Journal:  Obstet Med       Date:  2011-12-08

9.  mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regeneration.

Authors:  Shailesh Agarwal; David Cholok; Shawn Loder; John Li; Christopher Breuler; Michael T Chung; Hsiao Hsin Sung; Kavitha Ranganathan; Joe Habbouche; James Drake; Joshua Peterson; Caitlin Priest; Shuli Li; Yuji Mishina; Benjamin Levi
Journal:  JCI Insight       Date:  2016-12-08

10.  PET/CT of fibrodysplasia ossificans progressiva.

Authors:  Robert Kulwin; Larry A Binkovitz
Journal:  Pediatr Radiol       Date:  2009-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.